Small Cap Stocks To Follow Now – September 22nd

Spring Valley Acquisition, Boxlight, AgriFORCE Growing Systems, MBX Biosciences, and MBX Biosciences are the five Small Cap stocks to watch today, according to MarketBeat’s stock screener tool. Small-cap stocks are shares of companies whose total market value typically falls between about $300 million and $2 billion. Because these firms are smaller and less established, their shares often offer higher growth potential but also come with greater volatility and lower liquidity than larger-cap stocks. Investors include small caps in portfolios to seek above-average returns in exchange for accepting increased risk. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.

Spring Valley Acquisition (SV)

Boxlight (BOXL)

Boxlight Corporation designs, produces, and distributes interactive technology solutions for the education, health, corporate, military, and government sectors in the Americas, Europe, the Middle East, Africa, and internationally. The company provides interactive and non-interactive flat panel displays and whiteboards, LED video walls, digital signages, classroom audio and campus communication, cameras and other peripherals, and media players; and accessory document cameras, teacher pads for remote control, assessment systems, and front-of-class display products under the Mimio and Clevertouch brands.

AgriFORCE Growing Systems (AGRI)

AgriFORCE Growing Systems Ltd., an agriculture-focused technology company, focuses on the development and commercialization of plant-based ingredients and products that deliver healthier and nutritious solutions. The company operates in two divisions, AgriFORCE Solutions and AgriFORCE Brands. It also offers management advisory services and holds intellectual property, as well as engages in the real estate holding and development activities.

MBX Biosciences (MBX)

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.

MBX Biosciences (MBX)

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.